Regen Biopharma (RGBP) Stock Surges On Consulting Agreement With Biotech Research

There has been no fresh news about Regen Biopharma Inc (OTCMKTS:RGBP) this morning but that has not stopped the stock from going on a strong rally and clocking gains of 27% so far.

Regen Biopharma (RGBP) Stock Surges On Consulting Agreement With Biotech Research

However, it is important to point out that on Tuesday, it emerged that the company signed a consulting agreement with Biotech Research Group Corporation. Biotech Research Group is regarded as an FDA Specialist and Global Regulatory and Scientific Experts.

The Group is going to be engaged in helping Regen Biopharma with regards to its plan to reinstate the inactive IND (investigational new drug) applications that are now lying with the United States Food and Drug Administration. The signing of the agreement marks the first step for Regen Biopharma towards reactivating those applications. Last month, the Regen stock had emerged as one of the major gainers after its pancreatic cancer treatment was licensed by Oncology Pharma. Investors could consider tracking the stock today.

Richard McEntire

Finance and Entertainment Reporter Richard is a bottle of wine - the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.